Study Title:
A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib; Melphalan; and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation
Lead Group:
Status:
Review Status: